Actionable news
All posts from Actionable news
Actionable news in BMRN: BioMarin Pharmaceutical Inc.,

BioMarin (BMRN) Q1 Earnings: Stock Likely to Beat Estimates

BioMarin Pharmaceutical Inc. BMRN is slated to report first-quarter 2016 results on Apr 28.

BioMarin’s track record has been satisfactory so far. The company reported a narrower-than-expected loss in three of the trailing four quarters, with an average negative surprise of 8.98%.

View photo


Let’s see how things are shaping up for this quarter.

Factors at Play

Vimizim and Kuvan, which boosted sales in the previous quarter, are likely to have generated higher revenues in the to-be-reported quarter as well. In addition, the launch of Vimizim in new markets should contribute to the top line.

The company’s efforts on expanding Vimizim’s reach in established markets to bring new patients onto therapy at a faster pace and introducing the drug in new markets in each quarter should drive revenues. For the full year, Vimizim sales are expected to be $300–$330 million.

Meanwhile, adoption of the American College of Medical Genetics and Genomics practice guidelines to raise awareness on the benefits of Kuvan and its importance in the life-long treatment of phenylketonuria, which had increased the utilization of the drug in both adolescents and adults, should continue to accelerate growth.

Having regained the...